drugset / Trial / NCT06832267
Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL
NaSingle-groupOpen-labelTreatment
Summary
This study aims to observe and explore the efficacy and safety of Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) regimen as first-line therapy for primary central nervous system diffuse large B-cell lymphomas(PCNS DLBCL)
Timeline
- Start
- 2025-02-14
- Primary completion
- 2027-02-13
- Completion
- 2028-02-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Methotrexate | Small molecule | 1.5 g | Intravenous |
| Subject | Methotrexate | Small molecule | 3.5 g | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Subject | Temozolomide | Small molecule | 150 mg/m2 | — |
| Subject | Thiotepa | Other / unclassified | 40 mg/m2 | Intravenous |